amir lerman (rochester, usa) 11.54 (12’) cells at the moment of truth: recent findings from...

MADRID. SPAIN, MAY 12th - 13th 2016

AULA MAGNA. PABELLÓN DOCENTE. HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN.

C/ IBIZA, 43. 28007 MADRID

Symposium Director: Francisco Fernández – Avilés

SCIENTIFIC AGENDA

www.cardiovascularcelltherapy.com

13 th INTERNATIONAL

SYMPOSIUM

& ON STEM CELL THERAPY

CARDIOVASCULAR

INNOVATIONS

3


1

INTRODUCTION

2

SCIENTIFIC AGENDA

3

ORGANIZATION

4

EDUCATIONAL OBJECTIVES

5

ACCREDITATION

6

GENERAL INFORMATION

7

WEBSITE

8

FACULTY

9 COLLABORATION AND SPONSORSHIP

& 13 th INTERNATIONAL

SYMPOSIUM


ON STEM CELL THERAPY

CARDIOVASCULAR

INNOVATIONS

5

Global is

better!!

The Olympic Games represent the overwhelming force that nations joining together

has for the benefit of human values. Reaching unthinkable goals, proving that be-

yond these goals, the peoples' integrated effort makes all of them as well as each and

every one of us increasingly better.

The great advances in cardiovascular medicine have also depended on the globaliza-

tion of scientific efforts. Regenerative medicine is undoubtedly the greatest future

hope in the battle against cardiovascular failure and has the urgent need to address

this challenge within an international framework of excellence. To critically reflect on

the past, to advance through the synergy of basic discoveries and translational clini-

cal efforts from dedicated centres all around the world, and to finally establish the

goals for the next decade under a common umbrella.

This global view has inspired the mission of this symposium from the beginning. Once

again, this adventure has been made possible thanks to the effort and enthusiasm of

many people. With the celebration of the 13th Edition of this meeting, all of us who

have been involved in its preparation would like to thank you for your interest and

support. We sincerely hope to meet the expectations of all those who will devote

part of their valuable time to visit Madrid and to take part in the Symposium with us.

We are excited and look forward to sharing this special occasion with you.

Francisco Fdez-Avilés.

(On behalf of the Organizing Committee)

L'important dans la vie ce n'est point le triomphe, mais le combat, l'essentiel ce n'est pas d'avoir vaincu

mais de s'être bien battu

Pierre de Frédy, Baron de Coubertin (1863-1937).

Founder and father of the International Olympic Spirit

INTRODUCTION 1

7

SCIENTIFIC AGENDA 2

7.45 – 8.30 REGISTRATION

8.30 – 9.00 WELCOMING

9.00 – 10.00 OPENING LECTURES

Chairs John F. Martin (London, UK) André Terzic (Rochester, USA) 9.00 – 9.15 Dynamics of Cell Generation and Turnover in the Human Heart Olaf Bergmann (Stockholm, Sweden) 9.15 – 9.30 Biological basis of cardiac regeneration and repair. Obstacles and opportunities L. Maximiliam Buja (Houston, USA) 9.30 – 9.45 Organ interspecies manufacturaring. What about the heart? Juan Carlos Izpisúa (La Jolla, USA) 9.45-10.00 Obstacles for clinical research in cardiac regenerative medicine: The BAMI experience Andreas Zeiher (Frankfurt, Germany)

10.00 – 10.30 Coffee break and Poster Exhibition 10.30 – 12.30 WHAT’S NEW IN CARDIOVASCULAR REGENERATIVE MEDICINE?

Chairs Andreas Zeiher (Frankfurt, Germany) Piero Anversa (Lugano, Switzerland) Panel Discussants Bernardo Nadal-Ginard (Boston, USA) Felipe Prosper (Pamplona, Spain) Roberto Fdez-Viña (Buenos Aires, Argentina) Mariann Gyöngyössi (Viena, Austria)

THURSDAY, 12th May 2016

8

10.30 (12’) Old and young fellows in the cardiomyocyte party: how the heart grows? Annarosa Leri (Lugano, Switzerland) 10.42 (12’) Cells vs cells: comparative efficacy of different cells in ischemic cardiac and non-cardiac scenarios Giulio Pompilio (Milan, Italy) 10.54 (12’) Cells, and cells again: lessons from the REPEAT trial Birgit Assmus (Frankfurt, Germany) 11.06 (12’) Different cells together: novel insights from large animal studies. Joshua Hare (Miami, USA) 11.18 (12’) Beyond cells: past and future of gene therapy in cardiac repair. Marc S. Penn (Akron, USA) 11.30 (12’) Instead of cells: just geometry. Lessons from the AUGMENTED-HF trial Stephan von Haehling (Gottingen, Germany) 11.42 (12’) More than cells: engineering for vascular and valvular application Amir Lerman (Rochester, USA) 11.54 (12’) Cells at the moment of truth: recent findings from systematic reviews and meta-analyses (STEMI and heart failure) Enca Martin-Rendon (Oxford, UK) 12.06 – 12.30 Panel Discussion

12.30 – 13.15 Lunch and Poster Exhibition Chairs and jury: Philippe Menasché (Paris, France) Felipe Prosper (Pamplona, Spain) In this “Poster Exhibition” research teams involved in the topic of the Symposium will have the opportunity of presenting selected parts of their work to the audience A Poster Review Committee will select which the best posters of the session are. At the end of the session, the verdict will be communicated. The winner of the Posters Awards will have to present their work (oral presentation) the following day in the morning, in the session named “Best Poster Presentation”, when they will receive their prize. For more information regarding Poster Exhibition and Poster Awards, please contact us via e-mail at [email protected]

9

13.15 – 13.30 POSTERS AWARD—WINNERS COMMUNICATION

Chairs : Philippe Menasché (Paris, France) Felipe Prosper (Pamplona, Spain)

13.30 – 16.00 THIS YEAR WE DEBATE AGAIN

Chairs : Bernardo Nadal-Ginard (Boston, USA) Stefan Janssens (Leuven, Belgium) Panel discussants: Ricardo Sanz-Ruiz (Madrid, Spain) Roberto Bolli (Louisville, USA) Amir Lerman (Rochester, USA) Jerôme Roncalli (Toulouse, France) 13.30 – 14.10 The eternal debate: cell generation and turnover in the mammalian heart 13.30 (12’) Complement of cardiomyocytes remains stable over the human lifespan. Olaf Bergmann (Stockholm, Sweden) 13.42 (12’) Cardiomyocyte death and new cardiomyocytes formation occur throughout life. Piero Anversa (Lugano, Switzerland) 13.54 – 14.10 Panel Discussion 14.15 – 15.05 Lost in translation. The debate of preclinical research methodology 14.15 (12’) Rules and methodology of clinical science are required for research in animal models. Steven Chamuleau (Utrecht, The Netherlands) 14.27 (12’) Pathological assessment of cardiac regenerative experiments should be standardized. External core-labs are mandatory L. Maximilian Buja (Houston, USA) 14.39 (12’) The idea is more important than the experiment. Let us do. John F. Martin (London, UK)

14.51 – 15.05 Panel Discussion

10

15.10 – 16.00 Seeking alternatives to heart transplantation. Biology versus mechanics in end-stage heart failure 15.10 (12’) Cells alone are enough. We don’t need tissue engineering Stefanie Dimmeler (Frankfurt, Germany) 15.22 (12’) Mechanical circulatory support is already the answer and is improving dramatically. Neil Howell (Birmingham, UK) 15.34 (12’) Tissue engineering and organogenesis are the natural alternative and will be the answer soon. Doris A. Taylor (Houston, USA) 15.46 – 16.00 Panel Discussion

16.00 – 16.15 Coffee Break

16.15 - 18.10 DISCOVERIES, INVENTIONS AND BREAKDOWNS

Chairs: Kai C. Wollert (Hannover, Germany) Javier Bermejo (Madrid, Spain) Discussants Douglas W. Losordo (New York, USA) Doris A. Taylor (Houston, USA) Emerson C. Perin (Houston, USA) Steven Chamuleau (Utrecht, The Netherlands) 16.15 (12’) Cardiac stem cell hybrids enhance myocardial repair. Mark A. Sussman (San Diego, USA) 16.27 (12’) Exosomes as critical agents of cardiac regeneration Luis R. Borlado (Los Angeles, USA) 16.39 (12’) Cellular and non-cellular injectable biomaterials for cardiovascular repair. Karen L. Christman (San Diego, USA)

11

16.51 (12’) Stem cells for kids. Experience for hypoplastic left ventricle Timothy J. Nelson (Rochester, USA) 17.03 (12’) Human embryonic stem cell-derived cardiac progenitors for severe LV dysfunction. Here we are at last. Philippe Menasché (Paris, France) 17.15 (12’) Cells in left ventricular dysfunction. Any new? Anthony Mathur (London, UK) 17.27 (12’) Mayo clinical study on MSC in ischemic kidney disease Lilach O. Lerman (Rochester, USA) 17.39 (12’) Recent Breakdowns for clinical research Timothy Henry (Los Angeles, USA) 17.51 – 18.10 Panel Discussion

12

9.00 – 9.20 BEST POSTERS PRESENTATION

Chairs: Felipe Prosper (Pamplona, Spain) Philippe Menasché (Paris, France)

9.20 – 10.30 RECENT CONTRIBUTIONS PRESENTED BY YOUNG INVESTIGATORS

Chairs: Felipe Prosper (Pamplona, Spain) Philippe Menasché (Paris, France) Panel Discussants Jerôme Roncalli (Toulouse, France) Mark A. Sussman (San Diego, USA) Kai C. Wollert (Hannover, Germany) Roberto Bolli (Louisville, USA) 9.20 – 9.30 Personalized gene therapy targeting cardiac stem cells in patients affected

by Duchenne cardiomyopathy

Domenico D’Amario (Rome, Italy. Filippo Crea’s group)

9.30 – 9.40 The first prediction model for response to autologous bone marrow- derived mononuclear cells after myocardial infarction based on the RE PAIR-AMI trial Peter-Paul Zwetsloot (Utrecht, Netherlands. Steven Chamuleau’s group) 9.40 – 9.50 Epitranscriptonic modifications as a novel target in human CD34* stem cell-derived exosomes mediated cardiac repair Susmita Sahoo (New York, USA. Roger Hajjar’s group) 9.50 – 10.00 Comparison of Different Bone Marrow-Derived Stem Cell Approaches in Reperfused STEMI. A Multicenter, Prospective, Randomized, Open-Labeled TECAM Trial Ricardo Sanz-Ruiz (Madrid, Spain. Francisco Fdez-Aviles’s group) 10.00 – 10.10 Acellular human heart matrix: A critical step toward whole heart grafts. Mª Angeles Espinosa (Madrid, Spain. Francisco Fdez-Aviles’s group) 10.10 – 10.30 Panel discussion

10.30 – 11.00 Coffee Break

FRIDAY, 13th May 2016

13

11.00 –13.15 THE FIELD IN PERSPECTIVE

Chairs : Jens Kastrup (Copenhagen, Denmark)

José Luis Zamorano (Madrid, Spain)

Discussants: L. Maximilian Buja (Houston, USA) Rafael Matesanz (Madrid, Spain) Sol Ruiz (Madrid, Spain) James T. Willerson (Houston, USA) 11.00 – 11.15 From regulation to research. What’s happening? Thomas J. Povsic (Durham, USA) 11.15 – 11.30 Regeneration and the biology of the heart. Obstacles and opportunities Mark A. Sussman (San Diego, USA) 11.30 – 11.45 From cardiac regeneration biology to health. Are we really learning from animal models? Roberto Bolli (Louisville, USA) 11.45 - 12.00 Challenges in cardiac regeneration basic research. The ESC cellular biology working group perspective. Joost P. G. Sluitjer (Utrecht, The Netherlands)

12.00 – 12.15 Translation of knowledge into practical repair. Priorities, opportunities and risks of cardiac regenerative medicine Philippe Menasché (Paris, France) 12.15 – 12.30 Working together to advance in CV regenerative medicine. The CCTRN-NIH American example Emerson C. Perin (Houston, USA) 12.30 – 12.45 Planning cardiovascular regeneration for the next decade. The TACTICS enterprise Francisco Fdez-Avilés (Madrid, Spain) 12.45 – 13.15 Panel Discussion

13.15 – 13.45 Break

14

13.45 – 14.05 CLOSING SESSION

Chairs: Rafael Matesanz (Madrid, Spain) Arturo Fernández-Cruz (Madrid, Spain) 13.45 – 14.05 Cardiovascular regenerative medicine in the next decade. Should we stop or not? James T. Willerson (Houston, USA)

14.10 – 14.30 THIRD MADRID CARDIAC REGENERATION AWARDS

Chairs: Rafael Matesanz (Madrid, Spain) John F. Martin (London, UK)

14.30 ADJOURN

Francisco Fdez-Aviles (Madrid, Spain)

16

ORGANIZATION 3

DIRECTION Francisco Fernández-Avilés Servicio de Cardiología Hospital General Universitario Gregorio Marañón (Madrid, Spain) Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) CO-DIRECTION Andreu M. Climent Servicio de Cardiología. Laboratorio de Órganos Bioartificiales Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañon (Madrid, Spain)

Mª Eugenia Fernández Santos Unidad de Producción Celular. Laboratorio de Organos Bioartificiales Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañon (Madrid, Spain)

Bernard Gersh Mayo Clinic (Rochester, USA)

John F. Martin Centre for Cardiovascular Biology & Medicine (London, United Kingdom)

José Alberto San Román Instituto de Ciencias del Corazón (ICICOR) Hospital Clínico-Universitario de Valladolid (Valladolid, Spain)

Pedro L. Sánchez Servicio de Cardiología Hospital Clínico Universitario de Salamanca (Salamanca, Spain)

Ricardo Sanz Ruiz Servicio de Cardiología Hospital General Universitario Gregorio Marañón Instituto de Investigación Sanitaria Gregorio Marañon (Madrid, Spain)

Doris A. Taylor Texas Heart Institute (Houston, USA)

Andreas W. Zeiher University of Frankfurt (Frankfurt, Germany)

17

TECHNICAL DIRECTION

Ana Fernández Baza Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) Servicio de Cardiología Hospital General Universitario Gregorio Marañón

INTERNATIONAL SCIENTIFIC ADVISORY BOARD

EXECUTIVE LOCAL COMMITTEE Lucía Alvaredo Olmos Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) - Hospital G. Universitario Gregorio Marañon, Madrid Marta Hurtado Martín Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) - Hospital G. Universitario Gregorio Marañon, Madrid Enrique Gutiérrez Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) - Hospital G. Universitario Gregorio Marañon, Madrid Alberto Perez Castellanos Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) - Hospital G. Universitario Gregorio Marañon, Madrid Mª Eugenia Vázquez Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) - Hospital G. Universitario Gregorio Marañon, Madrid Adolfo Villa Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) - Hospital G. Universitario Gregorio Marañon, Madrid

ORGANIZATION

Instituto de Investigación Sanitaria Hospital Gregorio Marañón.

Servicio de Cardiología. Hospital General Universitario Gregorio Marañón, Madrid.

Red Temática de Investigación Cardiovascular del Instituto de Salud Carlos III (RIC)

Red Temática de Terapia Celular del Instituto de Salud Carlos III (TERCEL)

Grupo de Terapia Celular Aplicada al Miocardio (TECAM, Hospital General Universitario Gregorio Mara-ñón -Madrid-, Hospital Clínico-Universitario de Valladolid, Hospital Río Hortega - Valladolid-, Instituto de Biología y Genética Molecular - Universidad de Valladolid-)

Task Force on Stem Cell Regeneration of the Heart (European Society of Cardiology)

Jozef Bartunek (Aalst, Belgium) John F. Martin (London, United Kigdom)

Nabil Dib (San Diego, USA) Philippe Menasché (Paris, France)

Stefanie Dimmeler (Frankfurt, Germany) Bernardo Nadal-Ginard (Boston, USA)

Valentín Fuster (New York, USA) Emerson C. Perin (Houston, USA)

Juan Carlos Izpisúa (La Jolla, USA) Doris A. Taylor (Houston,USA)

Stefan Janssens (Leuven, Belgium) William Wijns (Aalst, Belgium)

Anthony Mathur (London, United Kingdom) James T. Willerson (Houston, USA)

18

This symposium is aimed at both medical and non-medical scientists interested in the study and appli-cation of stem cell therapy and other biotechnological advances for the prevention and treatment of cardiovascular failure. For this reason the audience comprises:

a. Preclinical researchers from all areas wishing to deepen their knowledge of cardiovascular bio-technological developments with therapeutic potential.

b. Doctors specialising in the care of patients suffering from cardiovascular diseases, and who are interested in finding out and discussing the current and the future prospects of these new therapeutic methods

c. Interventional cardiologists and cardiac surgeons interested in the results and perspectives of: gene vehiculization techniques, stimulation of endogenous progenitors, cell transplantation delivery systems or electromechanical devices to fight against cardiovascular diseases.

d. Medical or no medical professionals interested in the development of units and networks aimed at the translation of cardiovascular knowledge from bench to bedside and vice versa.

e. Medical or no medical professionals interested in envisaging the opportunities for competition of biotechnology in the cardiovascular field

At the end of the conference the attendees will have acquired the following skills:

1. Knowledge and ability to discuss the role of in the role of progenitor cells in the integrity of the cardiovascular system of a healthy individual.

2. Knowledge and ability to discuss the latest experimental advances on cardiovascular repair, through adult or embryonic stem cell transplantation, or by stimulation of endogenous progen-itors

3. Knowledge and ability to objectively debate the current state of feasibility, safety and efficacy with regards to the clinical application of cell therapy and other new biotechnological treat-ments.

4. Knowledge and ability to debate objectively on the efficiency of these types of treatment in patients with acute or chronic cardiovascular diseases.

5. Ability to predict the possibilities of scientific and professional attitude with regards to offering these therapeutic methods.

6. Ability to evaluate and decide one’s own ability to participate in the application of these thera-pies for healthcare, clinical, and preclinical purposes.

7. Ability to identify those institutions and groups with the highest performance capabilities in these fields, and to establish contacts for educational, scientific, and healthcare purposes.

EDUCATIONAL OBJECTIVES 4

19

ACCREDITATION 5

· Spanish Society of Cardiology.

Continuing Medical Education Accreditation Program. Activity accredited

by the Spanish Society of Cardiology for 9.6 credit hours.

· Comisión de Formación Continuada. Sistema Nacional de Salud. Activity

accredited.

20

GENERAL INFORMATION 6

MEETING VENUE

Aula Magna. Pabellón Docente. Hospital General Universitario Gregorio Marañón.

C/ Ibiza, 43. 28007 Madrid, Spain

DATE

May 12h and 13th , 2016

OFFICIAL LANGUAGES

English and Spanish (simultaneous translation will be available)

TECHNICAL SECRETARIAT

Viajes Orbiazul

C/ Alonso Pesquera, 2

47002 Valladolid

Tf. 00 34 983 30 91 22

Fx. 00 34 983 29 53 51

[email protected]

[email protected]

RETIRO

21

WEBSITE 7

The website www.cardiovascularcelltherapy.com is a virtual place which contains all the information related to this Symposium and its previous editions

It is possible through this web-site to access the scientific program, to register and to reserve accom-modation.

It is also a priority for this web site to offer updated information about Stem Cell Therapy for Cardio-vascular Diseases, so appropriate access to related sites has been created.

You can also join us on Facebook and Twitter.

@cardiostemcell

http://www.cardiovascularcelltherapy.com/

22

FACULTY 8

Piero Anversa (Lugano, Switzerland)

Birgit Assmus (Frankfurt, Germany)

Olaf Bergmann (Stockholm, Sweden)

Javier Bermejo (Madrid, Spain)

Roberto Bolli (Louisville, USA)

Luis R. Borlado (Los Angeles, USA)

L. Maximilian Buja (Houston, USA)

Steven Chamuleau (Utrech, The Netherlands)

Karen L. Christman (San Diego, USA)

Domenico D’Amario (Rome, Italy)

Stefanie Dimmeler (Frankfurt, Germany)

Mª Ángeles Espinosa (Madrid, Spain)

Francisco Fdez-Aviles (Madrid, Spain)

Arturo Fdez-Cruz (Madrid, Spain)

Roberto Fdez-Viña (Buenos Aires, Argentina)

Mariann Gyöngyösi (Viena, Austria)

Joshua Hare (Miami, USA)

Timothy Henry (Los Angeles, USA)

Neil Howell (Birmingham, UK)

Juan Carlos Izpisúa Belmonte (La Jolla, USA)

Stefan Janssens (Leuven, Belgium)

Jens Kastrup (Copenhagen, Denmark)

Annarosa Leri (Lugano, Switzerland)

Amir Lerman (Rochester, USA)

Lilach O. Lerman (Rochester, USA)

Douglas W. Losordo (Boston, USA)

John F. Martin (London, UK)

Enca Martin-Rendon (Oxford, UK)

Rafael Matesanz (Madrid, Spain)

Anthony Mathur (London, UK)

Philippe Menasché (Paris, France)

Bernardo Nadal-Ginard (Boston, USA)

Timothy Nelson (Rochester, USA)

Marc S. Penn (Akron, USA)

Emerson C. Perin (Houston, USA)

Giulio Pompilio (Milan, Italy)

Thomas J. Povsic (Durham, USA)

Felipe Prosper (Pamplona, Spain)

Jerôme Roncalli (Toulouse, France)

Sol Ruiz (Madrid, Spain)

Susmita Sahoo (New York, USA)

Ricardo Sanz-Ruiz (Madrid, Spain)

Joost P. G. Sluitjer (Utrecht, The Netherlands)

Mark A. Sussman (San Diego, USA)

Doris A. Taylor (Houston, USA)

André Terzic (Rochester, USA)

Stephan Von Haehling (Gottingen, Germany)

James T. Willerson (Houston, USA)

Kai C. Wollert (Hannover, Germany)

José Luis Zamorano (Madrid, Spain)

Andreas Zeiher (Frankfurt, Germany)

Peter-Paul Zwetsloot (Utrecht, Netherlands)

23

COLLABORATION AND SPONSORSHIP 9

Main Sponsors

BIOTRONIK

BOSTON SCIENTIFIC

MEDTRONIC

ST JUDE MEDICAL

Sponsors

ABBOT VASCULAR

AMGEN

ASTRAZENECA

BIOSENSE WEBSTER

CARDIVA

FERRER

GENZYME

IZASA

MAQUET

PALEX MEDICAL

TIGENIX

24

TECHNICAL DIRECTION

Ana Fernández Baza

Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46. 28007 Madrid

T. 00 34 91 426 58 82 / F. 00 34 91 586 82 76

[email protected]

TECHNICAL SECRETARIAT

Viajes Orbiazul

C/ Alonso Pesquera 2. 47002 Valladolid

T. 00 34 983 30 91 22 / F. 00 34 983 29 53 51

[email protected]

DIRECTION

Francisco Fernández-Avilés

Instituto de Investigación Sanitaria Gregorio Marañón

Hospital General Universitario Gregorio Marañón (Madrid, Spain)

CO-DIRECTION

Andreu M. Climent



Mª Eugenia Fernández Santos



Bernard Gersh

Mayo Clinic (Rochester, USA)

John F. Martin

Centre for Cardiovascular Biology & Medicine (London, United Kingdom)

José Alberto San Román

Hospital Clínico-Universitario de Valladolid (Valladolid, Spain)

Pedro L. Sánchez

Hospital Universitario de Salamanca (Salamanca, Spain)

Ricardo Sanz Ruiz



Doris A. Taylor

Texas Heart Institute (Houston, USA)

Andreas W. Zeiher

University of Frankfurt (Frankfurt, Germany)

ACCREDITATION ORGANIZED BY

Fundación Innovación en Biomedicina

amir lerman (rochester, usa) 11.54 (12’) cells at the moment of truth: recent findings from...

Documents